8-K: Travere Therapeutics Reports Strong Third Quarter 2024 Results Driven by FILSPARI Growth

Travere Therapeutics announced positive third quarter 2024 financial results, highlighted by the full FDA approval and strong sales growth of FILSPARI.

Summary

• Travere Therapeutics reported a net product sales of $61.0 million for the third quarter of 2024, with total revenue reaching $62.9 million.
• FILSPARI net product sales were $35.6 million for the quarter, with 505 new patient start forms received.
• Research and development expenses were $51.7 million, a decrease from $60.6 million in the same period of 2023, due to restructuring and reduced sparsentan development costs.
• Selling, general, and administrative expenses were $65.6 million, down from $67.8 million in the third quarter of 2023, also due to restructuring and cost-saving initiatives.
• The company reported a net loss of $54.8 million, or $0.70 per basic share, compared to a net income of $150.7 million, or $1.97 per basic share, for the same period in 2023.
• As of September 30, 2024, Travere had $277.4 million in cash, cash equivalents, and marketable securities.
• The company has scheduled a meeting with the FDA to discuss a potential regulatory pathway for FILSPARI in FSGS.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong sales growth for FILSPARI and full FDA approval, but the net loss and delay in the pegtibatinase program temper the overall sentiment.

Positives

• FILSPARI's full FDA approval expands its availability to more patients with IgAN.
• The company has seen a meaningful increase in demand for FILSPARI following full approval.
• The draft KDIGO guidelines recommend FILSPARI as a foundational kidney-targeted therapy.
• FILSPARI has shown superior long-term benefits on proteinuria and kidney function preservation compared to irbesartan.
• The company has made progress in reducing R&D and SG&A expenses through restructuring and cost-saving initiatives.
• The company has a strong cash position of $277.4 million.

Negatives

• The company reported a net loss of $54.8 million for the third quarter of 2024.
• The company has paused enrollment in the Phase 3 HARMONY Study of pegtibatinase due to manufacturing process improvements.
• The earliest date to restart enrollment in the Phase 3 HARMONY Study is expected to be in 2026.

Risks

• The company faces risks related to the timing and outcome of clinical studies.
• There are uncertainties associated with the regulatory review and approval process.
• The company faces risks related to the commercial launch of FILSPARI, including market acceptance and competition.
• There is a risk that the company will be unable to raise additional funding if required.
• The company faces risks associated with manufacturing scale-up.
• There is no guarantee that regulators will grant approval of sparsentan for FSGS.

Future Outlook

The company is well-positioned to further accelerate growth with FILSPARI, with plans to discuss a potential regulatory pathway for FILSPARI in FSGS with the FDA and continue the commercial launch in Europe. The company expects to provide an update on the FSGS program by its fourth quarter 2024 earnings call.

Management Comments

• Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics, stated that the company's performance in the third quarter was exceptional.
• Eric Dube also noted that the company has seen a meaningful increase in demand for FILSPARI since full approval.

Industry Context

The full FDA approval of FILSPARI and its inclusion in draft KDIGO guidelines positions Travere Therapeutics as a key player in the treatment of IgAN. The company's focus on rare kidney diseases aligns with the growing need for specialized treatments in this area.

Comparison to Industry Standards

• Travere's FILSPARI is the only non-immunosuppressive treatment that has shown significant slowing of kidney function decline in IgAN, setting it apart from traditional treatments.
• The company's focus on proteinuria reduction as a key endpoint aligns with current trends in nephrology research.
• The company's commercial launch of FILSPARI in Europe through CSL Vifor is similar to other pharmaceutical companies that partner to expand their reach.
• The company's R&D spending is in line with other biotech companies focused on late-stage clinical development.

Stakeholder Impact

• Shareholders will be impacted by the positive financial results and the full FDA approval of FILSPARI.
• Patients with IgAN will benefit from the expanded availability of FILSPARI.
• Employees may be impacted by the restructuring and cost-saving initiatives.
• The company's partners, such as CSL Vifor, will be impacted by the commercial launch of FILSPARI in Europe.

Next Steps

• The company will meet with the FDA to discuss a potential regulatory pathway for FILSPARI in FSGS.
• The company will continue the commercial launch of FILSPARI in the U.S. and Europe.
• The company will evaluate the necessary commercial process improvements to enable the continuation of the Phase 3 pegtibatinase program.
• The company expects to provide an update on the FSGS program by its fourth quarter 2024 earnings call.

Key Dates

Keywords

FILSPARI, sparsentan, IgAN, FSGS, kidney disease, FDA approval, clinical trials, Travere Therapeutics, financial results, pegibatinase, HARMONY Study